Lagevrio
(Molnupiravir)Phase 3Small molecule
Merck & Co.Molnupiravir is an antiviral medication used to treat mild to moderate COVID-19 in adults at high risk of severe illness. It works by interfering with the virus's ability to copy itself in the body.[1] Lagevrio is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Lagevrio is one of 151 small molecule programs targeting Viral Disease. It is currently in Phase 3.
4
Indications
24
Total Trials
7
Active Trials
150
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
332 competitors in Treatment
#DrugCompanyPhaseTrials
1Lagevrio
Merck & Co.Phase 3
Dexilant
TakedaPreclinical
Alfenta
Jazz PharmaceuticalsPreclinical
Niclocide
BayerPreclinical
Hivid
CConrado Roberto Hoffmann Filho
Preclinical
Valium
Akero TherapeuticsPreclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Clomid
FerringPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-1913 trials
Show 10 more trials
Influenza2 trials
Tics1 trial
Cohort Study1 trial
TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2
Completed·—··NCT05195060·1,178 enrolled
6 more indications
Moderate Hepatic Impairment1 trial
Adult1 trial
Renal Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Molnupiravir. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company